607 related articles for article (PubMed ID: 19253209)
1. [LHRH analogues for the treatment of prostate cancer: an evidence level-based analysis].
Pfitzenmaier J; Altwein JE
Aktuelle Urol; 2009 Mar; 40(2):100-8. PubMed ID: 19253209
[TBL] [Abstract][Full Text] [Related]
2. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
[TBL] [Abstract][Full Text] [Related]
3. Endocrine treatment of prostate cancer.
Tammela T
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
[TBL] [Abstract][Full Text] [Related]
4. [First line indications for hormonal therapy in prostate cancer].
Boccon-Gibod L; Richaud P; Coloby P; Coulange C; Culine S; Davin JL; Soulié M; Zerbib M
Prog Urol; 2010 Feb; 20(2):109-15. PubMed ID: 20142051
[TBL] [Abstract][Full Text] [Related]
5. Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy.
Moreau JP; Delavault P; Blumberg J
Clin Ther; 2006 Oct; 28(10):1485-508. PubMed ID: 17157109
[TBL] [Abstract][Full Text] [Related]
6. Combined androgen blockade: the gold standard for metastatic prostate cancer.
McLeod DG; Crawford ED; DeAntoni EP
Eur Urol; 1997; 32 Suppl 3():70-7. PubMed ID: 9267789
[TBL] [Abstract][Full Text] [Related]
7. The role of luteinizing hormone-releasing hormone therapy in locally advanced prostate cancer and biochemical failure: considerations for optimal use.
Teillac P; Bono AV; Irani J; Wirth MP; Zlotta AR
Clin Ther; 2005 Mar; 27(3):273-85. PubMed ID: 15878381
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant hormonal ablative therapy before radical prostatectomy: a review. Is it indicated?
Scolieri MJ; Altman A; Resnick MI
J Urol; 2000 Nov; 164(5):1465-72. PubMed ID: 11025684
[TBL] [Abstract][Full Text] [Related]
9. The role of radical prostatectomy in patients with clinically localized prostate cancer and a prostate-specific antigen level >20 ng/ml.
Bastide C; Kuefer R; Loeffler M; de Petriconi R; Gschwend J; Hautmann R
Prostate Cancer Prostatic Dis; 2006; 9(3):239-44. PubMed ID: 16832384
[TBL] [Abstract][Full Text] [Related]
10. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.
Calais da Silva FE; Bono AV; Whelan P; Brausi M; Marques Queimadelos A; Martin JA; Kirkali Z; Calais da Silva FM; Robertson C
Eur Urol; 2009 Jun; 55(6):1269-77. PubMed ID: 19249153
[TBL] [Abstract][Full Text] [Related]
11. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
Kobayashi T; Nishizawa K; Mitsumori K
Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
[TBL] [Abstract][Full Text] [Related]
12. [Neoadjuvant therapy of prostate carcinoma].
Ebert T
Praxis (Bern 1994); 1997 Nov; 86(46):1815-8. PubMed ID: 9454282
[TBL] [Abstract][Full Text] [Related]
13. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study.
Siddiqui SA; Boorjian SA; Inman B; Bagniewski S; Bergstralh EJ; Blute ML
J Urol; 2008 May; 179(5):1830-7; discussion 1837. PubMed ID: 18353378
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant hormonal therapy in the management of prostate cancer: a surgical and radiation therapy review.
Soderdahl DW; Wettlaufer JN; Corn B; Gomella LG
Tech Urol; 1996; 2(4):194-206. PubMed ID: 9085540
[TBL] [Abstract][Full Text] [Related]
15. [Hormone therapy of locally advanced and metastatic prostate carcinoma].
Rübben H
Praxis (Bern 1994); 2001 Sep; 90(38):1641-4. PubMed ID: 11675917
[TBL] [Abstract][Full Text] [Related]
16. [Clinical study of prostate specific antigen failure after radical prostatectomy for prostate cancer: a single center experience].
Taue R; Takahashi M; Fukawa T; Koizumi T; Nakanishi R; Yamaguchi K; Yamamoto Y; Nakatsuji H; Kishimoto T; Izaki H; Oka N; Fukumori T; Kanayama HO
Hinyokika Kiyo; 2009 Jan; 55(1):1-4. PubMed ID: 19227203
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant hormonal treatment before radical prostatectomy.
Watson RB; Soloway MS
Semin Urol Oncol; 1996 May; 14(2 Suppl 2):48-55; discussion 55-6. PubMed ID: 8725891
[TBL] [Abstract][Full Text] [Related]
18. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
19. Survival benefit for early hormone ablation in biochemically recurrent prostate cancer.
Tenenholz TC; Shields C; Ramesh VR; Tercilla O; Hagan MP
Urol Oncol; 2007; 25(2):101-9. PubMed ID: 17349523
[TBL] [Abstract][Full Text] [Related]
20. [Neoadjuvant hormonal therapy for prostate cancer].
Miki T; Kamoi K
Gan To Kagaku Ryoho; 2001 Jul; 28(7):927-33. PubMed ID: 11478141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
